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The prognosis of patients with refractory/relapsed acute myelogenous leukemia (rAML) is poor. Recent
studies have shown that more transplant centers are choosing allogeneic peripheral blood stem cell trans-
plantation (allo-PBSCT) for recipients, even with a higher leukemia burden. The purpose of the present study
is to evaluate the outcome of rAML patients undergoing allo-PBSCT and to determine whether the disease
status can predict the post-transplantation survival. The outcome of 58 patients (median age, 34 years; range,
14 to 52) with rAML who underwent allo-PBSCT in our institution from January 2000 until September 2011
was retrospectively studied. Thirty-three patients had complete remission (CR) before PBSCT, whereas 25
patients had no remission. Donors were matched related (31 patients) and unrelated (27 patients). Reduced-
intensity conditioning was used for 18 patients with rAML, and myeloablative conditioning was used for
others. Sixty-six consecutive non-rAML patients (median age, 33 years; range, 15 to 51) who received an allo-
PBSCT at the same period were used as a control. Full donor-type engraftment was achieved in all patients.
After a median follow-up of 61 months, the 5-year overall survival of rAML patients was 54.21%  7.06%,
which was lower than non-rAML patients (71.82%  6.4%, P ¼ .0386). However, the 5-year event-free survival
for rAML and non-rAML patients had no statistical signiﬁcance (53.54%  6.87% versus 62.07%  6.78%, P ¼
.2626). The 5-year overall survival between rAML patients who had CR and no remission before PBSCT was
56.06%  9.2% and 51.85%  10.83%, respectively (P ¼ .6408). These data demonstrate that allo-PBSCT is
a promising and safe choice for the treatment of rAML, and the results were partially due to the rapid tapering
of immunosuppressants in the early stage after PBSCT and prophylactic donor lymphocyte infusion. Mean-
while, the patients who did not achieve CR before PBSCT could also beneﬁt from allo-PBSCT.
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Despite intensive remission induction chemotherapy, the
clinical outcomes of relapsed/refractory acute myelogenous
leukemia (rAML) are dismal. Further improvements in
survival are unlikely to be achieved with traditional ap-
proaches such as standard or even high-dose chemotherapy
[1-3]. Otherwise, a high incidence of relapses in those who
already obtained remission after chemotherapy is a major
hindrance to the long-term survival of patients with AML;
even higher relapse rates appeared in rAML patients because
of the larger tumor burden. Therefore, the treatment of
patients with rAML remains challenging [4-6].
Allogeneic hematologic stem cell transplantation (HSCT)
is a curative treatment for refractory or relapsed acute
leukemia, and it has been shown to decrease the risk of
disease relapse when compared with chemotherapy and is
now established as the treatment of choice in eligible
patients with rAML [7-10]. Advanced transplantation strat-
egies have increased the survival by 10% per decade [11]. The
improved transplantation protocol for high-risk patientsedgments on page 659.
quests: Jian-Min Wang, Department of
Second Military Medical University,
ail.com.cn (J.-M. Wang).
contributed equally to this work.
2013 American Society for Blood and Marrow
13.01.015remission (CR) [12] and can cure approximately one third of
patients with primary refractory AML [13]. With convenient
collection and faster neutrophil and platelet engraftment,
more transplant centers are choosing allogeneic peripheral
blood stem cell transplantation (allo-PBSCT) for recipients,
and several advancements have reduced the toxicity associ-
ated with HSCT [14-18]. Unfortunately, long-term survival of
allo-PBSCT is limited by the morbidity and mortality related
to relapse of the primary disease and complications of HSCT.
The long-term beneﬁts of the PBSCT and whether all rAML
patients should beneﬁt from it remain controversial [19,20].
The growing number of survivors creates a need to optimize
the PBSCT procedure and identify whether the disease status
and some other factors related to patients’ characteristics
and transplantation procedures can affect the outcome of
transplantation. Thus, we retrospectively examined the
potential factors affecting the outcome of 58 patients with
rAML in comparison with 66 consecutive non-rAML patients
who underwent allo-PBSCT at our center between January
2000 and September 2011.
METHODS
Patient Characteristics
Patients were included in the rAML group if they fulﬁlled the following
criteria: primary failure to achieve a CR after two cycles of standard
induction therapy, relapse after a ﬁrst CR of fewer than 6 months, second orTransplantation.
Table 1
Patient and Transplant Characteristics
Characteristics rAML Non-rAML P
Recipient n ¼ 58 n ¼ 66
Median age, yr (range) 34 (14-52) 33 (15-51) .953
Age, no. (%) .653
30 years 25 (43) 24 (36)
>30 years 33 (57) 42 (64)
Gender, no. (%) .538
Female 20 (34) 24 (36)
Male 38 (66) 42 (64)
Disease state before HCT, no. (%) 0
CR
CR1 0 (0) 43 (65)
CR2 0 (0) 23 (35)
CR2 33 (57) 0 (0)
Relapse or NR 25 (43) 0 (0)
Bone marrow blasts, % (range) 19 (0-47) 2 (0-4) 0
Cytogenetics, no. (%) .051
Normal 20 (34) 47 (71)
Abnormal 25 (43) 13 (20)
Poor risk* 7 (28) 3 (23)
Unknown 13 (23) 6 (9)
Interval between diagnosis and
HCT, mean (range)
13 (2-70) 9 (3-48) .057
Gender match (donor/recipient),
no. (%)
.541
Female to male 16 (28) 23 (35)
Others 42 (72) 43 (65)
Donor type, no. (%) .263
Matched related 31 (53) 41 (62)
Unrelated 27 (47) 25 (38)
Median age of donor, yr (range) 26 (18-42) 30 (16-52) .621
ABO blood types, no. (%) .886
Matched 32 (55) 26 (39)
Unmatched 26 (45) 40 (61)
HLA matching, no. (%) .128
Matched 46 (79) 51 (77)
Mismatched
1 allele 5 (9) 7 (11)
2 alleles 7 (12) 8 (12)
Conditioning regimen, no. (%) .062
Reduced-intensity (FBA) 18 (31) 39 (59)
Myeloablative (Non-FBA) 40 (69) 27 (41)
Median MNC, 108/kg (range) 5.2 (3.92-7.80) 5.1 (3.31-8.00) .085
Median CD34þ, 106/kg (range) 2.4 (.70-6.8) 2.5 (1.07-8.85) .979
Median ANC  .5  109/L time,
day (range)
13 (10-28) 13 (9-19) .276
Median PLT  20  109/L time,
day (range)
14 (9-60) 14 (12-26) .937
Acute GVHD, no. (%) .723
No 41 (71) 40 (60)
I 4 (7) 3 (5)
II 8 (14) 19 (29)
III-IV 5 (8) 4 (6)
Chronic GVHD no. (%) 57 66 .041
Absent 11 (19) 25 (38)
Limited 39 (68) 37 (56)
Extensive 7 (13) 4 (6)
Median follow-up, mean (range) 61 (3-132) 63 (3-130) .103
MNC indicates mononuclear cells.
* Poor risk: Philadelphia (Ph) chromosome-positive t(9;22), 5/
del5q, 7, 3q, or 11p abnormalities; translocations t(4;11), t(1;19), t (3;3),
t(6;9), inv (3) (q21;q26.2); and complex karyotypes (three or more chro-
mosome abnormalities).
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therapy [21-23]. In our center, AML patients with a suitable donor who
satisﬁed the above criteria proceeded directly to PBSCT without further
salvage chemotherapy if they also preferred HSCT. From January 2000 to
September 2011, 58 consecutive patients with rAML underwent allo-PBSCT
in our institute. Complete remission was deﬁned as <5% blasts in the bone
marrow and normalization of the peripheral blood count without circu-
lating blasts. Patients were not eligible for allo-PBSCT if they had severe
concomitant medical or psychiatric illnesses. Data on patients were
censored in December 2011.
All patients signed informed consent forms before starting the condi-
tioning therapy. Themedian bonemarrow blasts were 19% (range, 0% to 47%)
in the rAMLgroupbeforePBSCT. Themedianagewas34years old (range,14 to
52). Thirty-three of 58 rAML patients (57%) achieved CR before PBSCT,
whereas 25 patients (43%) had no remission (NR). Thirty-one patients had
a matched-related donor and 27 patients had unrelated donors. Twenty
unrelated donors came from the Chinese Marrow Donor Program, and
7 unrelated donors came from the Buddhist Tzu Chi Stem Cells Center.
Twenty ﬁve patients (43%) in the rAML group had chromosomal
abnormalities. Seven patients had poor chromosomal abnormality deﬁned
as follows: 5/del5q, 7, 3q, or 11p abnormalities; translocations t(4;11),
t(1;19), t (3;3), t(6;9), inv (3) (q21;q26.2); and complex karyotypes (three or
more chromosome abnormalities) [24].
For the purpose of comparing with the rAML group, we screened all
standard-risk AML patients who received an allo-PBSCT during the same
period with remission status before transplantation as the control group
(non-rAML group) in our institute with the following eligibility criteria: CR
after one or two cycles of primary induction chemotherapy, relapse only
once after CR of longer than 6 months, and attaining CR again after one or
two salvage therapies. These patients usually received one to three
strengthening chemotherapies while searching for the donor or preparing
for PBSCT. A total of 66 consecutive AML patients were included in the study
as the control. Themedian age of non-rAML groupwas 33 years (range, 15 to
51). Three patients in the non-rAML group had poor chromosomal
abnormalities.
The rAML and non-rAML groups were comparable in terms of age,
gender, human leukocyte antigen (HLA) matching, donor type, conditioning
regimen, and graft-versus-host disease (GVHD) prophylaxis (P > .05).
Detailed information about patients and transplant characteristics are listed
in Table 1.
HLA Typing
For all patients, genomic high-resolution typing by polymerase chain
reaction (PCR)-based sequence-speciﬁc primer or PCR-based sequence-
speciﬁc oligonucleotide probe techniques were used for HLA typing. HLA-A,
-B and -DRB1 were typed for patients with related donors and HLA-C and
-DQB1 were added in patients with unrelated donors. All patients with
related donor (n ¼ 31, 53%) were HLA fully matched (6/6), whereas for
patients with unrelated donors (n ¼ 27, 47%), 15 patients had a one-allele
mismatched donor (9/10 alleles), 3 patients a two-allele mismatched
donor (8/10 alleles), and the others a fully matched (10/10 alleles) donor.
Stem Cell Mobilization and Cell Counts
For PBSC mobilization, all donors were treated with granulocyte
colony-stimulating factor (5 mg/kg, administered subcutaneously once
daily) for 5 days before apheresis. In all rAML patients, the median number
of mononuclear cells infused was 5.2  108/kg (range, 3.92 to 7.8  108/kg)
recipient body weight, and the median number of CD34þ cells infused was
2.4  106/kg (range, .7 to 6.8  106/kg) recipient body weight.
Engraftment
Absolute neutrophil count (ANC) and platelets (PLT) were used to
evaluate graft function. We recorded the time of the ﬁrst 3 consecutive days
when ANC was .5  109/L and PLT was 20  109/L after PBSCT. Platelet
engraftment satisﬁed the following conditions: (1) no platelet transfusion
was given on or between the ﬁrst and third days of counts and (2) the three
counts were at least 24 hours apart. The gender chromosome and/or real-
time PCR of short tandem repeat were used for chimerism monitoring.
Graft-Versus-Host Disease
Acute GVHD (aGVHD) was graded in ﬁve degrees [25]: 0 or absent and
grades I, II, III, and IV. Only patients alive on day 100 were eligible for
chronic GVHD (cGVHD) evaluation and outcome analysis, whichwas divided
into limited and extensive groups [26].
Conditioning Regimen and GVHD Prophylaxis
Reduced-intensity conditioning (RIC) transplantation was developed to
reduce the toxicity of conditioning regimens, decrease the incidence ofGVHD, and preserve a curative antitumor effect corresponding to allo-HSCT
[27-29]. To further optimize the outcome of RIC transplantation for acute
leukemia, in 2007, 5 years ago our transplantation center designed an RIC
regimen we named FBA consisting of ﬂudarabine, cytosine arabinoside, and
busulfan. To ensure its usefulness in rAML patients, 18 patients (31%) with
rAML were prepared with RIC-FBA (ﬂudarabine, 30 mg/m2/day on
days 10 to 6; busulfan, .8 mg/kg every 6 hours on days 5 to 3;
cytosine arabinoside, 1.5 g/m2/day on days 10 to 6 i.v.), whereas other
rAML patients received myeloablative conditioning regimen, including
30 patients (52%) conditioned with cyclophosphamide (60 mg/kg/day for
2 days) and total body irradiation (total 7 to 8 Gy; 6 to 7 Gy for lungs) with
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administered busulfan (.8 mg/kg every 6 hours for 4 days i.v.) and cyclo-
phosphamide (60 mg/kg/day for 2 days i.v.). Antithymocyte globulin
(Fresenius , Germany, 5 mg/kg/day for 4 days i.v.) was supplied to patients
undergoing unrelated donor PBSCT.
GVHD prophylaxis consisted of cyclosporine A (CsA), methotrexate, and
mycophenolate mofetil. Methotrexate was administered at doses of 15 mg
on day 1 and 10mg on days 3 and 6 after PBSCT. Mycophenolate mofetil was
administered at doses of 1 g twice a day from day 1 until day 30 after
transplantation. Intravenous CsA (2 to 3mg/kg daily) was administered from
day 2 to day þ30 until no gastrointestinal reaction occurred; the patient
was then switched to oral drug administration (4 to 5 mg/kg daily). We
measured the plasma CsA levels once a week after PBSCT and kept the level
between 200 and 400 ng/mL. After transplantation, the patients who had no
aGVHD at the early stagewould have CsA rapidly tapered. For these patients,
CsA was tapered from day þ45 to þ90 and discontinued by day þ120. From
day þ60 prophylactic donor lymphocyte infusion (DLI) was recommended
in patients without aGVHD. At our center, frozen storage donor-derived
stem cells grafts were used as the source of DLI. It was given in a dose-
escalating way to achieve a sustained graft-versus-leukemia (GVL) effect
with limited risk of GVHD. DLI was repeated at 4- to 6-week intervals up to
three times with the initial cell dose of 1 to 2  106 CD3þ cells/kg, increased
to 3 to 4  106 CD3þ cells/kg if no GVHD occurred, and ﬁnally increased to
8 to 10  106 CD3þ cells/kg. Other supportive care included lipo-
prostaglandin E1 20 to 30 mg/day given for prophylaxis of veno-occlusion
disease and blood components infusion according to institutional
guidelines.
Statistical Analyses
Data on patients were censored in December 2011. Transplantation-
related data were measured from the date of HSCT to that of disease
progression or death from any event (in the case of event-free survival
[EFS]), of death from any cause (in the case of overall survival [OS]), of
relapse (in case of relapse rate [RR]), and of transplant procedureerelated
death (in the case of treatment-related mortality [TRM]). On the date of
last follow-up in patients without the respective event, the data were
censored. Actuarial probabilities of OS, EFS, TRM, and RR were calculated
using the Kaplan-Meier method, and the log-rank test (univariate) was used
to evaluate differences between curves.
Statistical analyses comparing demographic and disease-speciﬁc vari-
ables used the t test for continuous variables and the chi-square test for
categorical variables. SPSS 11.5 was used to perform the statistical analyses
(Statistics Institute, SecondMilitaryMedical University, Shanghai, China). All
P values were two sided, with P ＜ .05 indicating statistical signiﬁcance by
single analysis. The 95% conﬁdence interval (CI) was calculated for standard
error computation.
RESULTS
Engraftment
All 58 rAML patients and 66 non-rAML patients achieved
engraftment. The day tomedian ANC> .5109/L and the day
tomedian PLT> 20109/Lwere 13 days (range,10 to 28 days)
and 14 days (range, 9 to 60 days) in rAML, respectively. The
difference of engraftment time between the rAML andFigure 1. (A) Overall survival and (B) event-free survival of 58 patients with refractor
relapsed acute myelogenous leukemia.non-rAML group was not statistically signiﬁcant (P ¼ .276
[ANC]; P ¼ .937 [PLT]). At day þ30, all patients had donor
chimerism, and no primary graft failure was observed.
Acute and Chronic GVHD
aGVHD was scored in four patients (7%) as grade Ⅰ, eight
patients (14%) as grade Ⅱ, and ﬁve patients (8%) as gradea Ⅲ
to Ⅳ in rAML at a median of 28 days (range, 7 to 82).
Compared with the rAML group, grades Ⅰ, Ⅱ, and Ⅲ to Ⅳ
aGVHD appeared in, respectively, 3, 19, and 4 patients (5%,
29%, and 6%) of non-rAML group at a median of 30 days
(range, 8 to 84) (P¼ .723). Except for one patient who died of
severe aGVHD with infection, 57 rAML patients survived
longer than 100 days after PBSCT and were eligible for
evaluation of cGVHD. Forty-six patients (81%) developed
cGVHD at a median of 157 days (range, 101 to 904) in the
rAML group, including 39 patients (68%) with limited cGVHD
and 7 patients (13%) with extensive cGVHD. The incidence of
cGVHD in the rAML group was higher than that in the non-
rAML group (P ¼ .041). Detailed information about GVHD is
listed in Table 1.
Forty-one rAML patients (71%) who had no aGVHD
underwent a rapidly tapered CsA. Among them, 22 patients
(54%) had prophylactic DLI, including 10 patients with DLI
only one time, 8 patients twice, and 4 patients three times.
After DLI, aGVHD grades Ⅱ toⅢwas triggered in nine patients
(41%), whereas cGVHD was triggered in six patients (27%).
The median time of aGVHD and cGVHD occurring after DLI
was 25 days (range,17 to 53) and 113 days (range,101 to 186),
respectively.
OS and EFS
The median follow-up in rAML and non-rAML was
61 months (range, 3 to 132) and 63 months (range, 3 to 130),
respectively. At time of last follow-up, 34 patients (59%) were
alive in the rAML group. Twenty-four patients in the rAML
group died due to relapse (n ¼ 12) and transplant-related
disease (n ¼ 12). Most deaths (95%) occurred within the ﬁrst
3 years after transplantation. The probability of 5-year OS in
rAML patients were 54.21%  7.06%. Fifty-one patients (77%)
in the non-rAML group were alive, and 8 patients died from
transplant-related disease and 7 patients from relapse.
Compared with rAML, the probability of 5-year OS in non-
rAML was 71.82%  6.4% (P ¼ .0386). (Figure 1A). However,
there was no statistical signiﬁcance in EFS between the two
groups. The probability of 5-year EFS in rAML and non-rAMLy/relapsed acute myelogenous leukemia and 66 patients with nonerefractory/
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(P ¼ .2626). (Figure 1B). Multivariate analysis showed no
signiﬁcant predictors of OS and EFF (Table 2).Relapse and TRM
Fifteen patients (26%) of all rAML experienced leukemia
relapse at a median of 6 months (range, 2 to 36) after trans-
plantation. Three patients who experienced relapse achieved
CR and sustained it after DLI with or without chemotherapy.
The other 12 patients died of relapse and failed to respond to
therapy. In all non-rAML patients, 13 patients (20%) experi-
enced leukemia relapse at amedian of 8months (range, 2.3 to
37.7) after transplantation. Seven patients died, and the other
6patients achievedand sustainedCRafterDLIwithorwithout
chemotherapy. The probability of 5-year RR was 30.9% 
6.85% in the rAML group and 26.6%  6.62% in the non-rAML
group (P ¼ .4194) (Figure 2A).
Twelve patients in the rAML group died of TRM, including
serious infection (n ¼ 5), interstitial pneumonia (n ¼ 3),
severe aGVHD (n ¼ 1), and extensive cGVHD with infection
(n ¼ 3). Eight patients in the non-rAML group died of TRM.
The causes of deathwere serious infection (n¼ 4), interstitial
pneumonia (n ¼ 3), and extensive cGVHD (n ¼ 1). The
probability of 5-year TRM was 25.11%  6.32% in the rAML
group and 14.22% 4.76% in the non-rAML group (P¼ .2076)
(Figure 2B). Multivariate analysis showed signiﬁcant
predictors of RR. Only the noneRIC-FBA conditioning
regimen was signiﬁcantly associated with a higher risk ofTable 2
Multivirate Cox Analysis of Independent Variables Affecting Transplantation Outco
Variables OS EFS
Relative risk (95% CI) P Relative risk
Age, no.
30 years 1 1
>30 years 1.2 (.4-3.1) .782 1.4 (.6-3.8)
Gender, no.
Male 1 1
Female .9 (.3-3.4) .956 .7 (.2-2.4)
Disease state before HCT, no.
CR 1 1
NR .9 (.3-2.6) .861 .9 (.3-2.6)
Cytogenetics, no.
Normal 1 1
Abnormal 3.8 ( .8-17.4) .08 2.2 (.6-8.9)
Unknown 3.4 (.7-16.6) .138 2 (.4-9.2)
Gender match (donor/recipient), no.
Female to male 1 1
Others .4 (.1-1.8) .241 .5 (.1-2.1)
Donor type, no.
Matched related 1 1
Unrelated 1.4 (.4-4.4) .605 1.3 (.4-4.5)
ABO blood types, no.
Matched 1 1
Unmatched 2.5 (.7-9.6) .166 2.7 (.8-9.6)
HLA matching, no.
Matched 1 1
Mismatched 1.6 (.5-5.7) .46 1.7 (.5-6)
Conditioning regimen, no.
Reduced-intensity 1 1
Myeloablative .3 (.1-1.1) .072 .3 (.1-1.2)
Acute GVHD, no.
No to I 1 1
II 2.4 (.3-2.8) .416 2.6 (.3-21.3)
III-IV 2.4 (.2-24.1) .464 2.4 (.2-23.5)
Chronic GVHD, no.
Absent 1 1
Limited 1.8 (.4-8.9) .465 1.8 (.4-8.6)
Extensive .9 (.1-8.5) .891 .9 (.1-8.8)TRM (relative risk, .5; 95% CI, .1 to .8; P ¼ .036), however
(Table 2).
Survival Analyses in rAML Patients with CR versus NR
before PBSCT
Thirty-three patients (57%) in the rAML group received
allo-PBSCT during CR and the rest of patients (43%) without
CR (NR). Twenty patients (61%) were alive in the CR group
and 14 patients (56%) in the NR group at the last follow-up.
The probability of 5-year OS for the CR and NR group were
56.06%  9.2% and 51.85%  10.83%, respectively (P ¼ .6408,
Figure 3A), whereas the EFS for the CR and NR groups were
53.42%  9.14%, and 51.59%  10.61%, respectively (P ¼ .7448,
Figure 3B). Eight patients (24%) experienced relapse after
PBSCT in the CR group and seven patients (28%) in the NR
group. The probability of 5-year RR for the CR and NR groups
were 29.7%  9.04% and 33.44%  10.86%, respectively
(P ¼ .6555, Figure 3C). Six patients in the CR group and
6 patients in the NR group died of transplant-related
complications. The probability of 5-year TRM for the CR
and NR groups were 22.13%  8.04% and 28.85%  10.02%,
respectively (P ¼ .5225, Figure 3D). Detailed information
about patients with CR and NR are listed in Table 3.
DISCUSSION
PBSCs replaced bone marrow as a stem cell source in
approximately 100% in the autologous and approximately
75% in the allogeneic transplantation setting [16]. Based onme in rAML Transplants
RR TRM
(95% CI) P Relative risk (95% CI) P Relative risk (95% CI) P
1 1
.45 2.5 (.7-9) .147 .4 (.1-3.6) .434
1 1
.589 .8 (.2-4.7) .841 2 (.2-17.8) .551
1 1
.883 .7 (.2-3) .674 .6 (.1-2.8) .494
1 1
.251 .7 (.1-3.6) .63 3.8 (.9-11.9) .056
.398 1.1 (.1-7.6) .997 1.1 (.5-5.4) .06
1 1
.386 1.2 (.2-6.8) .84 .4 (.1-2.3) .124
1 1
.582 1.6 (.3-8.5) .549 .6 (.1-3.4) .551
1 1
.126 1.2 (.2-6.7) .851 8.7 (.9-24.3) .051
1 1
.427 3.9 (.4-35.6) .228 .5 (.1-2.7) .44
1 1
.063 .4 (.1-2) .272 .5 (.1-.8) .036
1 1
.38 3.1 (.2-14.1) .947 1 (.1-12.5) .98
.462 3 (.1-15.3) .955 1.6 (.1-20.1) .756
1 1
.474 2.3 (.2-21.7) .472 .9 (.1-11.1) .956
.935 2.1 (.1-31.2) .597 .6 (.1-20.5) .747
Figure 2. (A) Relapse rate and (B) transplant-related mortality of 58 patients with refractory/relapsed acute myelogenous leukemia and 66 patients with non-
erefractory/relapsed acute myelogenous leukemia.
W.-P. Zhang et al. / Biol Blood Marrow Transplant 19 (2013) 653e660 657a variety of multicenter trials in leukemia patients, PBSCT,
compared with bone marrow transplantation, has a stronger
GVL effect, faster engraftment, less transplantation-related
complications, and a reduced treatment cost [30-33]. A
large registry reported that the incidence of cGVHD at 1 year
was signiﬁcantly greater in patients after PBSCT, and TRMFigure 3. The probability of overall survival (A), event-free survival (B), relapse (C), a
leukemia patients with CR or NR disease status before transplantation.and leukemia-free survival rates were in favor of patients
undergoing PBSCT in advanced stages of leukemia [15].
The role of stem cell transplantation in rAML is well
established and has been conﬁrmed as mandatory for cure. It
can reduce relapse signiﬁcantly and induce long-termdisease
remission [34-36]. To verify and improve the outcome ofnd transplant-related mortality (D) in refractory/relapsed acute myelogenous
Table 3
Patients with CR and NR before PBSCT in rAML
Characteristics CR NR P
Recipient n ¼ 33 n ¼ 25
Median age, yr (range) 31 (20-52) 36 (14-49) .512
Gender, no. (%) .085
Female 15 (45) 5 (20)
Male 18 (55) 20 (80)
Bone marrow blasts, % (range) 2 (0-4.5) 26 (6.5-47) .093
Cytogenetics, no. (%) .289
Normal 13 (39) 7 (28)
Abnormal 16 (48) 9 (36)
Poor risk* 5 (31) 2 (22)
Unknown 4 (13) 9 (36)
Interval between diagnosis and
HCT, mean (range)
9 (5-70) 8 (2-69) .612
Gender match (donor/recipient),
no. (%)
.832
Female to male 6 (18) 10 (40)
Others 27 (82) 15 (60)
Donor type, no. (%) .844
Matched related 15 (45) 16 (64)
Unrelated 18 (55) 9 (36)
ABO blood types, no. (%) .058
Matched 15 (45) 17 (68)
Unmatched 18 (55) 8 (32)
HLA matching, no. (%) .663
Matched 25 (76) 21 (84)
Mismatched 8 (24) 4 (16)
Conditioning regimen, no. (%) .329
Reduced-intensity (FBA) 12 (36) 6 (24)
Myeloablative (non-FBA) 21 (64) 19 (76)
Median MNC, 108/kg (range) 5.11 (3.92-7.8) 5.17 (4.06-7.54) .223
Median CD34þ, 106/kg (range) 2.36 (.70-6.5) 2.4 (1.21-6.8) .492
Median ANC  .5  109/L time,
day (range)
14 (10-20) 13 (10-28) .863
Median PLT  20  109/L time,
day (range)
15 (9-50) 16 (11-60) .578
Acute GVHD, no. (%) .995
No to I 25 (76) 20 (80)
II 5 (15) 3 (12)
III-IV 3 (9%) 2 (8)
Chronic GVHD, no. (%) 33 24 .984
Absent 8 (15) 3 (13)
Limited 22 (65) 17 (71)
Extensive 3 (20) 4 (16)
Median follow-up, mean (range) 62 (3-132) 61 (3-130) .446
MNC indicates mononuclear cells.
* Poor risk: Philadelphia (Ph) chromosome-positive t(9;22), 5/
del5q, 7, 3q, or 11p abnormalities; translocations t(4;11), t(1;19), t (3;3),
t(6;9), inv (3) (q21;q26.2); and complex karyotypes (three or more chro-
mosome abnormalities).
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transplant-related factors that should affect outcome were
evaluated in the study presented here. It thus appears
possible to deﬁne patients with refractory or relapsed disease
who require more attention and therapy if we are to achieve
results comparable with those of non-rAML patients.
For patients with rAML, the most important thing is to
reduce the relapse rate and prolong survival. Almost all
previous publications have found a lower rate of survival and
higher rate of relapse for patients in refractory or relapsed
status before HSCT versus those in nonrefractory or relapsed
status. In a study with primary refractory AML, the 3-year
disease-free survival, OS, and RR were 31%, 30%, and 51%,
respectively [13].With high-dose chemotherapy before HSCT,
5-year EFS was 52% for refractory AML patients [37]. In our
study, we found that the 5-year OS was approximately 54% in
the rAMLgroup, a promising andacceptable result, although it
was still lower than that in the non-rAML group. Apparently,
the main reason for the lower OS in the rAML group was thatmost patientsdiedof relapse and transplant-relateddisease. It
is conceivable that a higher proportion of tumor cells in rAML
patients presents a higher relapse rate afterHSCT [38-40], but,
interestingly, no signiﬁcantdifferencewas found inEFSandRR
between rAML and non-rAML in the current cohort.
Considering the peripheral blood as graft, we hypothe-
sized that the stronger GVL effect plays a part in reducing the
incidence of relapse and improving the EFS. In addition, early
rapid tapering of immunosuppressants and prophylactic DLI
for rAML patients may also play an important role. The
indubitable existence of a GVL effect is difﬁcult to prove
directly, and it is the beneﬁcial aspect of the graft-versus-
host phenomenon, in particular cGVHD, after allogeneic
transplant [41-43]. Although poorly controlled GVHD is
associated with signiﬁcant morbidity and mortality, there
may be also beneﬁts from the GVL effect, including facilita-
tion of the engraftment process or prevention/treatment of
leukemia relapse [44].
We found no statistical signiﬁcance in terms of the 5-year
EFS, RR, and TRM between rAML and non-rAML patients,
whereas the incidence of cGVHD in the rAML group was
higher than that in the non-rAML group (P ¼ .041).We
presumed that the GVL effect triggered by cGVHDmight play
an important role in prevention of relapse, although GVHD
was not a signiﬁcant predictor of survival in multivariate
analysis. CsA was withdrawn rapidly in a stepwise fashion to
avoid overwhelming GVHD reactions if aGVHD did not
develop at the early stage [20]. In our study, 71% of rAML
patients discontinued CsA rapidly, which might enhance the
GVL effect and thus result in a higher EFS in rAML patients.
Prophylactic DLI can also augment allogeneic immune-
mediated antileukemia effect after allo-HSCT, and it has
been proven to induce remissions in patients with relapsed
hematologic malignancies after transplantation [45,46].
Prophylactic DLI has also been used as part of transplant
protocols in patients who have not relapsed, and it is inten-
ded to facilitate establishment of full donor chimerism and
potentiation of the antitumor effect [47]. Although we found
that 81% of rAML patients had cGVHD after PBSCT, and it was
higher than non-rAML patients, the rapid tapering of
immunosuppressants for GVHD in the early stage after PBSCT
and prophylactic DLI have an acceptable toxicity proﬁle and
may be a better approach to treating rAML.
The outcome of HSCT is associated with leukemia load
before transplantation, and this is one of the most important
factors predicting long-term survival in acute leukemia [48].
What is currently debated is whether a trial of reinduction
chemotherapy before transplantation is beneﬁcial for
patients with refractory and/or relapsed AML. For rAML
patients unlikely to respond, reinduction attempts may be
detrimental, leading to added organ toxicity and possible
increased tumor resistance. What should we do for these
patients? It is reported that the 2-yearOS rateswere66%, 40%,
and23% for patients inCRandwith activediseasewithout and
with circulating blasts at HSCT, respectively [49]. In our study,
we found that the patients with NR disease status before
PBSCTalso had a similar outcome comparedwith those in CR.
The rAML patients transplanted after CR may have less
advanceddiseasesbut are likely tohavebeenexposed tomore
chemotherapies, which may compromise their ability to
withstand conditioning. Therefore, in our analysis rAML
patients in CR versus NR have nearly identical survival.
For patients with NR disease status, we can also choose
allo-PBSCT as a salvage therapy method. Moreover, the rAML
patients who achieved CR before transplantation still needed
W.-P. Zhang et al. / Biol Blood Marrow Transplant 19 (2013) 653e660 659to be exposed to a conditioning regimen. The toxicity of the
myeloablative conditioning regimen administered before
transplantation remains the main factor leading to high
morbidity and mortality [50], especially for those refractory/
relapsed patients undergoing intensive remission induction
chemotherapy. RIC regimens have emerged as an attractive
modality to decrease TRM.Multivariate analysis in our report
also showed that noneRIC-FBA conditioning regimen was
signiﬁcantly associated with a higher risk of TRM. From this
we can see that the RIC-FBA regimen can reduce the incidence
of transplant-related disease and improve the long-term
prognosis of rAML patients after PBSCT. A report from our
center showed that the probability of OS in AML patients in
ﬁrst and secondCRwithRIC-FBA regimenatþ100days,1 year.
and 2 years was 97.10%, 81.84%, and 75.07%, respectively,
whereas the probability of disease-free survival were 97.10%,
80.27%, and 73.62%, respectively [51]. In this report, we also
used the RIC-FBA regimen in 18 rAML patients. Although the
number of patients is insufﬁcient and the observation time is
short, we await the complete analyses of the results.
Donor type is an important factor in allo-HSCT. In China,
most families have only one child because of national poli-
cies, and it is more difﬁcult to ﬁnd a matched related donor
than in other countries. Therefore, transplantation using an
unrelated donor is then considered with preference. Trans-
plantation using a matched unrelated donor offers outcomes
comparable with related donor HSCT due to current
molecular-based HLA typing and improvements in condi-
tioning regimens and/or supportive care [52,53]. Similar
results have also been found in our study. The OS, EFS, RR,
and TRM rates of rAML patients between the related donor
group and unrelated donor group were not statistically
different (data not shown).
In conclusion, our data suggest that allo-PBSCT is
a promising and safe choice for the treatment of rAML, even
with a higher leukemia burden. Except for OS, there was no
statistically signiﬁcant difference between rAML and non-
rAML patients in terms of EFS, RR, or TRM, partially due to
the rapid tapering of immunosuppressants in the early stage
and prophylactic DLI after allo-PBSCT. The rAML patients
who were not able to achieve CR before transplantation
could also beneﬁt from allo-PBSCT. Our small number of
patients deﬁnitelymakes some strong conclusions difﬁcult at
this stage, but it would be interesting to see what happens
with a longer follow-up of rAML patients.
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